Back

Notification report


Full notification file


General information

Notification Number
B/NL/21/009

Member State to which the notification was sent
Netherlands

Date of acknowledgement from the Member State Competent Authority
12/04/2021

Title of the Project
Application form for Ad26 clinical vectors and MVA-BN clinical vectors contained in investigational products for human use

Proposed period of release:
01/04/2021 to 01/04/2031

Name of the Institute(s) or Company(ies)
Centre for human drug research, The Netherlands;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Ad26 clinical vector is derived from the human Adenovirus group D type 26 (genus Mastadenoviridae)

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Human adenovirus type 26MastadenovirusHuman adenovirus group D-Type 26-

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known